Melbourne (Australia), Nantes, Lyon (France) 9 May 2012: Australian vaccine development company BioDiem
Ltd (ASX: BDM) today announced that it has begun a research collaboration with France-based VIVALIS
(Euronext code: VLS), a biopharmaceutical company with expertise in vaccine production technologies. The
collaboration involves investigation of the synergy of BioDiem’s proprietary virus, LAIV, and VIVALIS’ proprietary
cell line, EB66®.
Successful results from this investigation could be used as a basis for a new agreement between
the companies in order to test the feasibility of development of BioDiem’s LAIV as a vector in VIVALIS’ proprietary
cell line. Viral vector technology is used in vaccines to deliver immune-stimulating proteins into the body. VIVALIS
is undertaking this initial research to further the high potential value of this technology in BioDiem’s non-influenza
BioDiem has considerable in-house expertise around the Live Attenuated Influenza Virus (LAIV), having an
existing LAIV-based technology for the production of influenza vaccines, currently generating licensing revenues
in India and China. BioDiem has proposed developing the LAIV as a versatile ‘vector’ (carrier) technology, which
could be used to create a variety of new vaccines (both therapeutic and preventative). This proposed vector would
be developed to have the additional advantages of a good safety profile and low toxicity (as the virus backbone is
already weakened), excellent virus characterisation from extensive prior work, and the ability to be customised to
target particular diseases.
This initial collaboration involves VIVALIS confirming that BioDiem’s LAIV strains grow satisfactorily in VIVALIS’
proprietary cell line EB66® and examining any effects on the virus’ characteristics. During this stage BioDiem’s
long-term collaborator, and LAIV developer, the Institute of Experimental Medicine in St Petersburg, will send an
LAIV expert to work on-site with VIVALIS in France.
This initial program is estimated to take up to ten weeks. Following successful demonstrations of growth and
productivity, BioDiem will look to negotiate another agreement with VIVALIS regarding a longer-term research
project aimed at developing a stable LAIV vector technology incorporating EB66® as a base platform for growth.
“VIVALIS is an ideal vaccine development partner, with a strong commercial mindset, a history of successful
partnerships and great technology in the internationally established EB66® cell line. We are excited to be
beginning this collaboration and moving forward on the LAIV vector project” said BioDiem Chief Executive Officer,
Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, “Advancing the EB66®
platform into novel areas is an objective we have maintained from the initial launch of the platform. This
agreement with BioDiem, the second EB66® agreement since January 1st, continues these objectives by moving
our EB66® technology into applications like those being developed by BioDiem in the therapeutic and preventative
vaccine fields. We look forward to working with BioDiem in this program and the possibility of expanding our
relationship into a process development, a future commercial license and biomanufacturing agreement as we both
advance the field of vaccine design and development.”
Terms of the agreement were not disclosed.
About BioDiem Ltd
BioDiem is an ASX-listed company based in Melbourne with an international focus on discovering, developing and
commercialising world-class research and technology for vaccines. BioDiem’s lead technology is the Live
Attenuated Influenza Virus (LAIV) technology, which has been developed as an intranasal vaccine to prevent
infection from seasonal and pandemic influenza.
The LAIV influenza vaccine can be produced using egg-based and cell-based manufacturing methods.
The cell-based LAIV vaccine has completed a Proof of Concept (Phase II) clinical trial. The egg-based LAIV
vaccine technology is licensed to the World Health Organization as part of the Global Pandemic Influenza Action
Plan to Increase Vaccine Supply. This allows governmental and non-governmental organizations or private
companies in developing countries to produce seasonal and pandemic vaccines in eggs. The LAIV influenza
vaccine is marketed as Nasovac™ in India by the Serum Institute of India. The LAIV is also being explored as a
viral vector for use in the development of novel non-influenza vaccines.
In December 2011 BioDiem acquired Savine Therapeutics Pty Ltd. Savine is a platform technology for the design
of antigens for incorporation into vaccines targeting a range of different diseases.
About LAIV Technology
The Live Attenuated Influenza Virus (LAIV) vaccine was in-licensed from the Institute of Experimental Medicine in
St Petersburg, Russia, where it has been approved and used in its present form for over a decade in many
millions of people - children, adults and the elderly.
The LAIV is administered by nasal spray and induces a rapid immune response in the mucosal lining of the nose
and pharynx. The vaccines are based on ‘Master Donor Strains’ that have been rendered ‘cold adapted’ and
temperature sensitive, such that they will not replicate readily at temperatures above 33?C, as found in the lungs.
The administration of the live vaccine stimulates mucosal, cellular and humoral immune responses (which are
required to optimise the effective prevention of influenza), without causing the disease.
For additional information, please visit www.biodiem.com
Julie Phillips, Chief Executive Officer
Phone +61 3 9613 4100
Phone +61 3 8866 1224 / +61 422 557 107